Biogen (BIIB) PT Raised to $455 at Morgan Stanley as Aduhelm Debate Shifts to Timing
Tweet Send to a Friend
Morgan Stanley analyst Matthew Harrison raised the price target on Biogen (NASDAQ: BIIB) to $455.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
